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Abstract
Background: Malaria greatly impacts the health and wellbeing of over half of the world’s population. Promising malaria
vaccine candidates have attempted to induce adaptive immune responses to Circumsporozoite (CS) protein. Despite the
inclusion of potent adjuvants, these vaccines have limited protective efficacy. Conventional recombinant adenovirus (rAd)
based vaccines expressing CS protein can induce CS protein specific immune responses, but these are essentially equivalent
to those generated after use of the CS protein subunit based vaccines. In this study we combined the use of rAds expressing
CS protein along with rAds expressing novel innate immune response modulating proteins in an attempt to significantly
improve the induction of CS protein specific cell mediated immune (CMI) responses.
Methods and Findings: BALB/cJ mice were co-vaccinated with a rAd vectors expressing CS protein simultaneous with a rAd
expressing either TLR agonist (rEA) or SLAM receptors adaptor protein (EAT-2). Paradoxically, expression of the TLR agonist
uncovered a potent immunosuppressive activity inherent to the combined expression of the CS protein and rEA.
Fortunately, use of the rAd vaccine expressing EAT-2 circumvented CS protein’s suppressive activity, and generated a
fivefold increase in the number of CS protein responsive, IFNc secreting splenocytes, as well as increased the breadth of T
cells responsive to peptides present in the CS protein. These improvements were positively correlated with the induction of
a fourfold improvement in CS protein specific CTL functional activity in vivo.
Conclusion: Our results emphasize the need for caution when incorporating CS protein into malaria vaccine platforms
expressing or containing other immunostimulatory compounds, as the immunological outcomes may be unanticipated
and/or counter-productive. However, expressing the SLAM receptors derived signaling adaptor EAT-2 at the same time of
vaccination with CS protein can overcome these concerns, as well as significantly improve the induction of malaria antigen
specific adaptive immune responses in vivo.
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Introduction
Malaria is an infectious disease that continues to devastate
populations world-wide, causing nearly 1 million deaths annually,
and morbidity that overwhelms the medical capabilities of
developing countries. Most cases of Malaria are caused by an
infection with the protozoan parasite Plasmodium falciparum (P.
falciparum). P. falciparum infections are responsible for about 80% of
all malaria cases and around 90% of all malaria deaths [1]. It is
known that prophylactic vaccination of subjects with irradiated
sporozoites can result in 94% protection against subsequent malaria
infection, a result confirming that induction of protective immunity
to malaria antigens can be achieved, if the vaccine utilized is potent
enough and expresses the correct antigenic targets [2]. Unfortu-
nately, the large scale production of irradiated sporozoites for this
purpose has not been feasible, largely due to the difficulties
associated with cGMP production of this class of vaccine.
Significant efforts have been undertaken to create malaria
specific subunit vaccines. Some of the most successful malaria
vaccine studies to date have attempted to induce adaptive immune
responses to the P. falciparum CS protein. CS protein is an ,58 kD
surface protein composed of a middle repeat region consisting of
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containing a thrombospondin-like type I repeat region (TSR)
and an N terminal region that assists with liver cell attachment
(Figure S1) [3].
CS protein is found on the surface of P. falciparum sporozoites
and is also expressed in hepatocytes during liver infection by the
parasite. Induction of potent cellular immune responses to CS
protein by a prophylactic malaria vaccine could potentially
eradicate both sporozoites and infected hepatocytes, potentially
stopping the infection before clinical symptoms occur.
Multiple studies have demonstrated the importance of CD8
+ T
cell responses in combating murine malaria infections [4,5,6,7].
An oral salmonella vaccine expressing murine malaria derived CS
protein was capable of protecting antibody deficient animals [6].
In addition, passive transfer of CD8
+ T cells that recognize a
specific murine malaria CS protein antigen resulted in 100%
survival upon sporozoite challenge [5]. Ads expressing murine
malaria derived CS protein have been shown to be capable of
providing cytotoxic T cell mediated inhibition of parasite liver
stage development up to 93% [7]. One of the most successful
subunit malaria vaccines to date contain a hepatitis B viral surface
protein (HBsAg) CS fusion protein (referred to as RTS,S). Initial
formulations of the RTS,S based vaccines demonstrated little
protection. Subsequent trials combining several novel ‘‘AS’’ series
adjuvants, (the latter consisting of different preparations of
monophosphoryl lipid A (MPL) and a plant extract known as
QS21), with the HBsAg-CSP fusion protein (referred to as RTS,S/
ASO1B) improved induction of CS specific responses, but this
level of protection was still limited, suggesting that a more robust
CS protein specific immune response may be required to achieve
improved protection rates [8,9,10,11,12,13,14].
Recombinant adenoviruses (rAd) can be utilized to induce
potent adaptive immune responses to antigens that they are
genetically engineered to express. For example, rAd serotypes 5
and 35 expressing CS protein (Ad5.CS and Ad35.CS respectively)
are capable of inducing CS protein specific T and B cells in mice
similar to the levels induced by the RTS,S/ASO1B adjuvanted
vaccine [15,16]. These levels paralleled results achieved in mice
treated with a rAd35 vaccine expressing the P. Yoelli derived CS
protein, a vaccine that was also found to be capable of providing
up to a 92–94% inhibition of liver infection when vaccinated
animals were challenged intravenously (IV) with viable P. yoelli
sporozoites [17]. Combining rAd35CS and rAd5CS CS protein
expressing vaccines in a heterologous prime-boost regimen in
rhesus monkeys can induce a more potent T and B cell response
than use of either vaccine alone [18]. Heterologous prime-boost
vaccination regimens utilizing Ad35.CS and RTS,S/ASO1B have
also been analyzed and show significant improvement over either
vaccine platform alone [19]. However, the utilization of alternative
serotype rAds or chimp derived rAds as a vaccine platform may be
dangerous, as our studies and those of others have confirmed the
increased innate toxicity of non-Ad5 rAds [20]. Therefore,
improving the capability of rAd5 vaccines to induce more potent
antigen specific adaptive immune responses is a high priority in the
drive to find an efficacious malaria vaccine. In this study we sought
to improve CS protein specific CMI responses induced by CS
protein-expressing rAd5s by co-expression of innate immune
response modulating proteins by the vaccine platform.
The innate immune system plays an integral role in augmenting
and/or shaping the induction of antigen specific adaptive immune
responses [21]. A group of cellular receptors that recognize a variety
of pathogen derived antigens, known as the toll-like receptors
(TLRs), play a crucial role in identifying pathogen associated
molecular patterns (PAMPS), and then augmenting adaptive
responses to those PAMPS. We have previously confirmed that
rAds ability to induce innate and adaptive responses are dependent
upon several TLR’s, and that many of these responses are primarily
dependent upon MyD88 functionality [22,23]. We have also
recently demonstrated that when rAd5 vaccines engineered to
express a novel Eimeria tenella derived TLR agonist, rEA, are co-
administered with rAd5 vaccines expressing a target antigen there
was significant improvement in the ability of the vaccine to induce
antigen specific cellular immune responses [24,25,26]. Similarly, we
have recently confirmed that co-expression of adaptor proteins
derived from SLAM receptors signaling pathways can also augment
induction of beneficial immune responses to rAd expressed antigens
[27]. In the latter instance we utilized the SLAM family of receptors
adaptor protein (EAT-2), an adaptor protein known to mediate
SLAM receptor signaling in immune cells [27,28].
In this study, we determined what the impact of modulation of
innate immune responses during CS protein presentation would
have upon induction of subsequent CS protein specific immune
responses in vivo. Unexpectedly, use of a TLR agonist uncovered a
potent immunosuppressive activity inherent to the combined use
of rEA and CS protein, an activity that mitigated induction of any
CS protein specific adaptive immune responses. Fortunately,
expression of the SLAM receptors adaptor protein EAT-2
overcame and enlightened possible mechanisms underlying the
paradoxical CS protein immunosuppressive activity we uncovered
when stimulating TLR pathways.
Methods
Vector construction
The Open Reading Frame (ORF) of the P. falciparum CS protein
gene, composed of a codon optimized consensus of several P.
falciparum CS protein sequences (Figure S1), was incorporated into
plasmid pGA4 (GENEART, Burlingame, CA) and excised from
pGA4 using endonuclease NheI (NEB, Ipswich, MA). The excised
portion was subcloned into the pAd Shuttle vector containing a
CMV expression cassette. The resulting pAd-CSP shuttle plasmid
was linearized with PmeI restriction enzyme and homologously
recombined with the pAdEasyI Ad5 vector genome as previously
described yielding pAd-CSP [29]. Virus was amplified in HEK293
cells. Ad-CSP virus was purified using a CsCl2 gradient as
previously described [30]. Direct sequencing and restriction
enzyme mapping were carried out to confirm the fidelity of the
CS protein sequence. Construction of Ad-GFP, Ad-GFP/rEA,
and Ad-EAT2 was performed as previously described [26,27,31].
Animal procedures
All animal procedures were approved by the Michigan State
University Institutional Animal Care and Use Committee
(IACUC). Intravenous injections were performed in 8week old
BALB/cJ mice (Jackson Laboratory, Bar Harbor, ME) via retro-
orbital sinus in a volume of 200 mL of PBS. 8 weeks old male
BALB/cJ mice were injected intramuscularly (IM) into the tibialis
anterior of the right hindlimb. Total injected volume was 20 ml.
Splenocytes and plasma were collected. All procedures with rAds
were performed under BSL-2, and all vector treated animals were
maintained in ABSL-2 conditions. Care for mice was provided in
accordance with PHS and AAALAC standards.
Cytokine and chemokine analysis
Plasma levels of cytokines/chemokines were measured by a
mouse multiplex kit per manufacturer’s instructions (Bio-Rad,
Hercules, CA) via Luminex 100 technology (Luminex, Austin,
TX) as previously described [22].
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ELISA-based antibody assays were completed as previously
described [31]. High-binding flat bottom 96-well plates were
coated with 0.2 mg of purified CS protein per well in a volume of
100 mL and incubated overnight at 4uC. Plates were washed with
PBS-Tween (0.05%) then blocked with blocking buffer (3% bovine
serum albumin) for 1 hour at room temperature. Plasma was
diluted (1:50, 1:100, 1:200, 1:400) in blocking buffer.and added to
the wells and incubated for 1 hour at room temperature. Wells
were washed with PBS-Tween (0.05%) and HRP antibody (Bio-
Rad) was added at 1:4000 dilution in PBS-Tween. Tetramethyl-
benzidine (TMB) (Sigma-Aldich) was added to each well and the
reaction was stopped with 1N phosphoric acid. Plates are read at
450 nm in a microplate spectrophotometer. Subisotyping tittering
was completed with a hybridoma subisotyping kit (Calbiochem, La
Jolla, CA) with plasma dilutions of 1:50, 1:100. 1:200. 1:400.
Statistical analyses were performed using Student t-test.
Isolation of lymphocytes
Splenocytes from individual mice were prepared by physical
disruption of the spleen. The spleen was passed through a sterile
40 mm nylon mesh cell strainer (Fisher Scientific, Pittsburgh, PA).
Red blood cells were lysed using ACK lysis buffer (Invitrogen,
Carlsbad, CA) remaining cells were resuspended in RPMI 1640
supplemented with 10% FBS and penicillin/streptomycin/fungi-
zone [26].
ELISPOT analysis
ELISpots were performed in accordance to manufacturer’s
protocol using the Ready-set Go IFNc mouse ELISpot kit
produced by eBiosciences (San Diego, CA). Splenocytes were
stimulated ex vivo with 4 mg/mL of the .98% pure CS protein
immunodominant peptide NYDNAGTNL (amino acids 43–51 of
the CS protein sequence) (GenScript Piscataway, NJ) [32]. A
library of 15mers overlapping by 5 amino acids spanning the
entire CS protein non-repeating region was constructed and also
used to stimulate splenocytes ex vivo (Biosynthesis Inc., Lewisville,
TX). Spots were counted and photographed by an automated
ELISPOT reader system (Cellular Technology, Cleveland, OH).
Ready-set Go IFNc and IL-2 mouse ELISPOT kits purchased
from eBioscience (San Diego, CA).
Cell staining and flow cytometry
Splenocytes were stained with various combinations of the
following antibodies: PE-CD69, (3 mg/ml), FITC-CD8a, APC-
CD3, APC-Cy7-CD3, Alexa Floure700-CD8a, PerCpCy5.5-
CD19, PE-Cy7-NK1.1, PE-Cy7-TNFa, APC-IFNc (4 mg/ml)
(All obtained from BD Biosciences, San Diego, CA), and
PerCpCy5.5-IL-2 (4 mg/ml) (BioLegend, San Diego, CA). Cells
were incubated on ice with the appropriate antibodies for 30
minutes, washed, and sorted using an LSR II instrument and
analyzed using FlowJo software. For intracellular cytokines
staining, cells were surface stained, fixed with 2% formaldehyde
(Polysciences, Warrington, PA), permeabilized with 0.2% Saponin
(Sigma-Aldrich, St. Louis, MO), and stained for intracellular
cytokines. Large cells and debris were excluded in the forward-
and side-scatter plot, to minimize background levels of staining
caused by nonspecific binding of antibodies; we initially stained the
cells with CD16/32 FcR III/II antibody. In addition we included
the violet fluorescent reactive dye (ViViD, Invitorgen) as a viability
marker to exclude dead cells from the analysis [33]. Blood was
isolated by retro-orbital bleeds and PBMCs were isolated using
Lympholyte-Mammal (Cedarlane, Burlington NC).Tetramer
staining of PBMCs was completed using a PE conjugated MHC-
I (H2d) tetramer folded with the NYDNAGTNL peptide
generated at the NIH Tetramer Core Facility.
In vivo CTL assay
BALB/cJ were co-vaccinated with equivalent doses of Ad-CSP
and either Ad-GFP or Ad-EAT2 (totaling 2610
8 vps). At 14 days,
syngeneic splenocytes were isolated and pulsed with either an
irrelevant peptide or peptide specific to the Plasmodium falciparum
circumsporozoite antigen (NYDNAGTNL) for 1 hour at 37uC.
Irrelevant peptide pulsed cells were stained with 1 mM CFSE
(CFSE
Low) while CS protein-peptides pulsed cells were stained
with 10 mM CFSE (CFSE
High). Naı ¨ve and immunized mice were
injected with equivalent amount of both CFSE
Low and CFSE
High
stained cells via the retro-orbital sinus. After 18 hours splenocytes
were harvested and sorted on an LSRII flow cytometer. FlowJo
software was used to determine percentages of CFSE stained cells.
% Specific killing =1-((% CFSE
High/% CFSE
Low) immunized/(%
CFSE
High/% CFSE
Low) non-immunized).
Statistical analysis
Statistically significant differences in ELISpot assays were
determined using One Way ANOVA with a Student-Newman-
Keuls post-hoc test (p value ,0.05). For ELISA analysis, a t-test
was used to assess significance between treatments. For multipa-
rameter flow cytometry, a One Way ANOVA with a Student-
Newman-Keuls post-hoc test was used. For in vivo CTL assay, a
One Way ANOVA with a Student-Newman-Keuls post-hoc test
was used. All graphs in this paper are presented as Mean 6 SD
with the exception of graphs of ELISA data which use Mean 6
SE. GraphPad Prism software was utilized for statistical analysis.
Results
CS protein expressed from rAd5 based vaccines can
induce CS protein specific B and T cell responses
A rAd5 based vaccine expressing a codon optimized form of the
CS protein (Ad-CSP) was constructed (Figure S2), and a dose study
was initially performed to assess at what dose optimal CS specific B
and T cell responses could be detected. BALB/cJ mice were intra-
muscularly (IM) injected with varying doses of Ad-CSP ranging
from 1610
7 to 1610
9 virus particles (vps) per animal. At 14 days
post injection (dpi) splenocytes derived from the vaccinated animals
were harvested, and exposed to an immunodominant CS protein
derived peptide (NYDNAGTNL). Significantly increased numbers
of IFNc secreting splenocytes were noted in Ad-CSP vaccinated
mice treated with 5.0610
7 to 1.0610
9 vps, with peak numbers
achieved at a dose of 1.0610
8 vps/mouse. Higher Ad-CSP doses
resulted in a trend of decreasing, though not significantly less,
numbers of spot forming cells (SFCs) (Figure 1A). Interestingly this
phenomenon has also been observed by other groups, however an
explanation for this phenomenon has yet to be forwarded [15,34].
These finding were further supported in individual splenocytes
derived from the vaccinated animals, where CD8
+ T cell IFNc,
TNFa,andIL-2levelsweremeasured byintracellular staining(ICS)
using flow cytometry. IFNc and TNFa production peaked at the
5.0610
8 vps/mouse with similar decreasing trend occurring at
1.0610
9 vps/mouse. IL-2 producing cells were much lower in
percentage, with the greatest numbers being observed as the
5.0610
7 vps/mouse dose (Figure 1B). We will further discuss the
importance of these findings in the Discussion section.
To determine if Ad-CSP is also capable of stimulating B cell
responses specific to the CS protein, plasma was collected from the
vaccinated mice and assayed by a IgG CS protein specific ELISA
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all mice treated with Ad-CSP with a peak response occurring at
5.0610
7 vps/mouse, demonstrating Ad-CSP is capable of
stimulating a B cell response against CS protein even at the
lowest dose used in the study (Figure 1C).
The use of a TLR agonist unexpectedly reduces CS
protein specific cellular immune responses
Previous experiments confirm that expressing the TLR agonist
rEA from an Ad vector stimulates innate immune responses during
Ad mediated vaccination, responses that positively correlated with
improved induction of antigen specific adaptive immune responses
against several antigens, such as the HIV antigen, Gag [26]. In this
study, we sought to utilize rEA to improve induction of CS protein
specific immune responses. We first confirmed that expression of
rEA along with CS protein facilitated induction of pro-inflamma-
tory innate immune responses, responses we had noted in our
previous studies of rEA [26]. Plasma cytokine levels at 6 hours post
injection (hpi) in mice co-injected intravenously (IV) with either
3.75610
10 vps of Ad-CSP and 3.75610
10 vps Ad-GFP/rEA were
compared to responses measured after identical co-injections
utilizing an Ad-GFP expressing vector (that does not express rEA)
as a control (Figure 2). We observed significantly higher levels of IL-
6,IL-12(p40),G-CSF,MCP-1,MIP-1b, RANTES, KC,andTNFa
in mice treated with Ad-CSP+Ad-GFP/rEAas compared to control
virus treated animals, as well as, mock infected animals (Figure 2).
To assess the impact that these early increases in cytokine and
chemokine responses had on cell mediated immune (CMI)
responses to CS protein we IM co-injected 5610
7 vps/mouse of
Ad-CSP and 5610
7vps/mouse of Ad-GFP/rEA and compared
the induction of CS specific adaptive immune responses to those
noted in our control animals receiving 5610
7 vps/mouse of Ad-
CSP and 5610
7 vps/mouse of Ad-GFP IM, or mock infected
mice. Splenocytes derived from mock vaccinated animals did not
show the presence of CS protein specific CMI responses while Ad-
CSP+Ad-GFP confirmed induction of CS protein specific CMI
responses using ELISpot analysis (p,0.05) (Figure 3A). However,
despite the rEA enhanced activation of the innate immune
responses noted in Figure 2, ELISpot analysis of splenocytes
derived from Ad-CSP+Ad-GFP/rEA vaccinated animals con-
firmed a profound lack of induction of average CS protein specific
Figure 1. Ad-CSP Stimulates CS protein specific T and B cell responses. CS protein specific immune responses increase in an Ad-CSP dose
dependent manner. BALB/cJ mice (n=3) were injected IM with Ad-CSP ranging from 1610
7 to 1610
9 vps/mouse, increasing by half logs. 14 days
post injection splenocytes and plasma were collected. (A) ELISpot assays were performed to quantify IFNc secreting cells from splenocytes stimulated
with CS protein peptide, NYDNAGTNL, ex vivo. (B) IFNc, TNFa, and IL-2 expression by splenocyte derived CD3
+ CD8
+ T cells was analyzed by flow
cytometry following ex vivo stimulation with NYDNAGTNL. (C) Total IgG against CS protein was assessed by ELISA. The bars represent mean 6 SD.
Statistical analysis was completed using One Way ANOVA with a Student-Newman-Keuls post-hoc test, *,**,*** denotes significance over naı ¨ve,
p,0.05, p,0.01, p,0.001.
doi:10.1371/journal.pone.0024147.g001
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responses measured in naı ¨ve mice (p.0.05) (Figure 3A). Previously
we have not observed an ablation of CMI responses when CS
protein was co-administered with Ads expressing other antigens at
these low doses, further suggesting that this effect may be specific
to simultaneous TLR stimulation (Figure S3). Despite there being
no significant differences between CS protein responses in Ad-
CSP+Ad-GFP/rEA treated animals and naı ¨ve animals, we did
note that in one Ad-CSP+Ad-GFP/rEA animal there was some
evidence of an elevated CS protein specific response, indepen-
dently verifying that this group did in fact receive viable Ad-CSP
vector (Figure 3A).
Augmentation of the innate immune responses via SLAM
adaptor EAT-2, improves CS protein specific T-Cell
responses
Based upon the loss of CS protein responsiveness after utilizing
TLR mediated augmentation along with CS protein antigen
vaccination we hypothesized that the CS protein may have an
ability to mitigate induction of beneficial innate immune responses
in the context of excessive, TLR pathway mediated activation as the
ablated immune responses were only observed after Ad-GFP/rEA
doses exceeded 5610
6 vp/mouse (Figure S4). To attempt to test this
hypothesis, we made use of a recently described, alternative method
for augmenting induction of antigen specific adaptive immune
responses, utilizing Ad mediated co-expression of a SLAM receptor
signaling pathway adaptor, EAT-2, along with a targeted antigen
[27]. To accomplish this we co-injected 5610
7 vps/mouse of Ad-
CSP and 5610
7 vps/mouse of Ad-EAT2, and compared the
induction of CS specific adaptive immune responses to those noted
in the control mice receiving 5610
7 vps/mouse of Ad-CSP and
5610
7 vps/mouse of Ad-GFP IM, as well as mock vaccinated mice.
Again, splenocytes were collected at 14 dpi and stimulated with the
CS derived peptide NYDNAGTNL ex vivo. In dramatic contrast to
our previous results utilizing the Ad-GFP/rEA and Ad-CSP
vaccination strategy, splenocytes from mice co-treated with Ad-
CSP and Ad-EAT2 had significantly more IFNc secreting cells than
splenocytes from both mock injected mice as well as mice co-treated
with the control vaccine (p,0.05) (Figure 3B). Given these results,
we sought to further characterize the EAT-2 dependent improve-
ment in CS specific immune responses by flow cytometry.
Peripheral blood mononuclear cells (PBMC) derived from the
vaccinated animals were stained with CD3 and CD8 fluorescent
antibodies, as well as a NYDNAGTNL peptide loaded tetramer.
Ad-CSP+Ad-EAT2 treated mice had significantly higher percent-
ages of CS protein specific tetramer positive CD8
+cells present in
their PBMCs than the percentage noted in the Ad-CSP+Ad-GFP
Figure 2. TLR agonist, rEA, induced innate cytokines 6 hours post injection. Co-injection of Ad-GFP/rEA and Ad-CSP stimulated robust
expression of innate cytokines and chemokines as compared to the control vaccine. BALB/cJ mice were injected IV with either 3.75610
10 vps/mouse
of Ad-CSP+Ad-GFP or 3.75610
10 vps/mouse Ad-GFPrEA+Ad-CSP. Plasma was collected at 6 hours post injection. Plasma cytokine/chemokine levels
were measured with a mouse multiplexed bead array based quantitative system. The bars represent mean 6 SD. Statistical analysis was completed
using One Way ANOVA with a Student-Newman-Keuls post-hoc test, *,** denotes significance between treatments, p,0.05, p,0.01.
doi:10.1371/journal.pone.0024147.g002
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+ CD8
+ splenocytes were
additionally analyzed for IFNc and perforin by ICS using flow
cytometry. The percent of CD3
+ CD8
+ cells that secreted IFNc was
significantly higher in Ad-CSP+Ad-EAT2 treated mice as com-
pared to Ad-CSP+Ad-GFP treated control (p,0.05) (Figure 4B).
The percent of CS protein peptide specific CD3
+ CD8
+ perforin
+
cells also tended to be higher in animals given the Ad-EAT2+Ad-
CSP vaccination cocktails however this did not reach statistical
significance (Figure 4C). To confirm that the differences in the
responses observed are not a result of GFP antigens competing with
CS protein antigens, but are in fact a direct result of the expression
of EAT-2 we injected micewith either Ad-CSP+AdGFP or Ad-CSP
+ an empty Ad vector (Ad-Null). We observed no differences
between the treatments, indicating GFP does not interfere with
induction of CS protein specific CMI responses (Figure S5).
Increased breadth of CMI responses to a pathogen derived
protein has been shown to be beneficial relative to eventual
protection against actual pathogen challenge [35,36,37]. To detect
CMI responses against other peptides present within the CS
protein (and therefore to gauge the breadth of response against the
whole CS protein) we generated a CS protein specific peptide
library. This library consists of 15 mer peptides that overlap each
other by 5 amino acids and spans the non-repeating regions of the
full length CS protein. At 14 dpi, pooled splenocytes derived from
the control or experimental groups of vaccinated animals were
stimulated ex vivo with one 15mer peptide per well. Mice co-
vaccinated with Ad-CSP and Ad-GFP/rEA had an overall lower
breadth of response as is evident by the number of wells with more
than 15 spots (Figure 5A). In contrast to the response seen in rEA
treated animals, animals co-vaccinated with Ad-CSP and Ad-
EAT2 demonstrated a dramatic increase in breadth of response to
CS derived peptides when similarly analyzed (Figure 5B).
Co-injection of Ad-CSP and Ad-EAT2 improves the
cytolytic activity of CS protein specific T cells in vivo
To better assess the functional consequence of the improved CS
specific CMI responses noted by expression of EAT-2, we
stimulated splenocytes from naı ¨ve mice, mice vaccinated with
the control vaccine, and mice vaccinated with Ad-CSP+Ad-EAT2
with NYDNAGTNL ex vivo, then analyzed them by flow cytometry
for CD3
+, CD8
+ T cells that were also positive for a degranulation
marker, CD107a. Both control treated and Ad-CSP+Ad-EAT2
treated mice demonstrated significantly higher number of CD8
+,
CD107a
+ T cells than those quantified in naı ¨ve mice, indicating
increased ability of CD8
+ T cells to express granules when
stimulated with a CS protein epitope (Figure S6). However, the
assay was not sensitive enough to measure a difference between
the control vaccinated mice and Ad-CSP+Ad-EAT2 vaccinated
mice. We then conducted a more sensitive in vivo CTL assay [38].
Mice were co-vaccinated with either 1610
8 vp/mouse of Ad-CSP
and 1610
8 vps/mouse of Ad-GFP or 1610
8 vp/mouse of Ad-CSP
and 1610
8 vps/mouse of Ad-EAT2. 14 days later vaccinated mice
were treated with CFSE labeled splenocytes that had been
incubated with either the NYDNAGTNL peptide, or a non-
specific control peptide, and the elimination of NYDNAGTNL
pulsed cells (CFSE
high cells) was measured by flow cytometry.
Based on the calculated percent specific killing, animals vaccinated
with Ad-CSP+Ad-EAT2 were more effective at killing cells
exposed to the NYDNAGTNL peptide than animals vaccinated
with the control Ad-CSP vaccine (Figure 6).
Induction of CS protein specific antibody responses by
Ad-CSP vaccines augmented by rEA or EAT-2 expressing
rAds
CS protein antibody specific ELISAs were also performed on
plasma derived from Ad-CSP+Ad-GFP/rEA and Ad-CSP+Ad-
GFP treated animals. CS protein specific total IgG antibody
levels in control vaccine treated animals were significantly
elevated (p,0.05) as compared to naı ¨ve animals. However, there
was again no significant difference observed in Ad-CSP+Ad-
GFP/rEA treated animals when compared to naı ¨ve animals
(p,0.05) (Figure 7A). Conversely, plasma collected from Ad-
CSP+Ad-EAT2 treated animals had significantly higher levels of
CS protein specific IgG as compared to levels detected in naı ¨ve
mice (p,0.05) (Figure 7B). However, the mice receiving the
control vaccine treatment had higher total CS protein specific
IgG levels than naı ¨ve and Ad-CSP+Ad-EAT2 treated animals
(p,0.05) (Figure 7B). Further isotyping of IgG was performed,
the ratios of Th1t oT h2 antibody (IgG2a/IgG1) in mice treated
with Ad-EAT2+Ad-CSP were similar to the ratio of Th1t oT h2
antibody in control treated mice in all dilution except 1:400,
Figure 3. Immuno-modulating proteins conversely affect IFNc
secreting splenocytes. Co-vaccination with Ad-CSP and Ad-EAT2
dramatically increases IFNc secreting splenocytes in response to
stimulation with CS protein epitope, NYDNAGTNL. BALB/cJ mice were
injected IM with either 5610
7 vps/mouse of Ad-CSP and 5610
7 vps/
mouse Ad-GFP or 5610
7 vps/mouse of Ad-CSP and 5610
7 vps/mouse
of either (A) Ad-GFP/rEA (n=5) or (B) Ad-EAT2 (n=6). Splenocytes were
collected 14 days post co-injection. ELISpot were performed on the
splenocytes of these mice stimulated with NYDNAGTNL peptide to
assess the amount of IFNc secreting cells. The bars represent mean 6
SD. Statistical analysis was completed using One Way ANOVA with a
Student-Newman-Keuls post-hoc test,* Denotes significance over naı ¨ve
animals, p,0.05. Representative figures of two independent experi-
ments.
doi:10.1371/journal.pone.0024147.g003
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bias in these mice at 14 dpi as measured by this assay (Figure S7).
In addition, when measured by ICS, there was no significant
difference in the number of likely CD4+ IFNc expressing T-cells,
as the number of CD8
- CD3
+ T cells in Ad-CSP+Ad-EAT2
treated animals and were similar to the numbers of these cells
noted in Ad-CSP+Ad-GFP treated animals (Figure S8).
Discussion
Our earlier works and those of others suggest that activation of
the innate immune system can play an important role in
beneficially augmenting subsequent antigen specific adaptive
immune responses [22,26,39,40,41]. For example, we previously
augmented CMI responses against HIV-Gag by co-injecting a
rAd5 vector expressing HIV-Gag with a rAd5 vector expressing a
TLR agonist, rEA [26]. Similarly, co-injecting a rAd5 vector
expressing HIV-Gag with a rAd5 vector expressing the SLAM
receptors adaptor protein EAT-2 also augmented induction of
innate immune responses, and improved the induction of HIV-
Gag specific T cell responses [27]. As a new approach to
increasing the potency of malaria specific vaccines, we now
describe the use of adenoviral based vaccines engineered to
express malaria derived proteins, simultaneously administered
with rAds expressing proteins known to modulate the innate
immune system. Most importantly, we have confirmed that rAd
mediated expression of a SLAM pathway derived adaptor (EAT-2)
can significantly augment the induction of malaria antigen (CS
protein) specific CMI responses. This was verified based upon
ELISpost analysis of splenocytes (both as to their responsiveness to
immunodominant peptides, as well the breadth of these responses
to the full length CS protein), ICS staining of cells for IFNc, and
most importantly by a CS protein specific in vivo CTL functional
assay. EAT-2 expressing vaccines should be considered for use in
future malaria vaccine trials attempting to boost malaria antigen
specific CMI responses. Furthermore, EAT-2 co-expression
allowed for the induction of CS specific antibody responses as well.
In contrast, co-vaccination of mice with a rAd vaccine
expressing a TLR agonist simultaneously with a rAd expressing
CS protein, actually had the opposite effect, and completely
mitigated induction of CS protein specific adaptive humoral and
cellular immune responses, as compared to responses typically
induced by the rAd vaccines expressing CS protein alone. There
could be numerous reasons for these unexpected, paradoxical and
potentially disturbing results. A simple reason could be that the
increase in pro-inflammatory cytokines caused by rAd mediated
Figure 4. Co-expression of CS protein and EAT-2 stimulates more potent CS protein specific CMI responses. Co-vaccination with Ad-
CSP and Ad-EAT2 resulted in increased NYDNAGTNL tetramer positive CD8
+ T cells as well as improved IFNc secretion from CD8
+ T cells. BALB/cJ mice
(n=6) were co-injected IM with 5610
7 vps/mouse of Ad-CSP and 5610
7 vps/mouse of Ad-EAT2 or 5610
7 vps/mouse of Ad-CSP and 5610
7 vps/
mouse of Ad-GFP. (A) Peripheral Blood Mononuclear Cells (PBMCs) were stained with CD8-Alexa Flour700, CD3-APC-Cy7, and CSP (NYD)-Tetramer. (B–
C) Intracellular staining was performed on splenocytes after stimulation with NYDNAGTNL peptide. Cells were stained with CD8-Alexa Flour700, CD3-
APC-Cy7, ViViD, IFNg-APC, and Perforin-PE antibodies. The bars represent mean 6 SD. Statistical analysis was completed using One Way ANOVA with
a Student-Newman-Keuls post-hoc test, *, **, *** denotes significance over naı ¨ve animals, p,0. 05, p,0. 01, p,0.001.
doi:10.1371/journal.pone.0024147.g004
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expression of CS protein from the rAd5 vector. However, this
effect would have likely been observed in our previous studies
utilizing the same vector combinations, as well as the same TLR or
SLAM receptors derived adaptors, but a different target antigen
(HIV-Gag). Those studies also confirmed induction of similar
innate immune responses to those noted in this study [26,27]. It is
more logical that the CS protein somehow negatively interacts
with immune pathways excessively activated by TLR agonists such
as rEA, resulting in a complete ablation of CS protein specific
CMI responses. This immunosuppressive activity of CS protein
appears to only be unveiled after excessive stimulation of TLR
pathways, as our use of EAT-2 demonstrated not only avoidance
of CS immunosuppressive activity, but also allowed for enhanced
induction of CS specific adaptive immune responses.
The CS protein has been specifically confirmed to be capable of
outcompeting the transcription factor NF-kB for binding to the
nuclear transport protein, importan a, resulting in the downreg-
ulation of at least forty NF-kB controlled genes [42]. CS protein
was also shown to inhibit NF-kB entry into the nucleus by 75%
[42]. As NF-kB is known to control numerous genes involved in
pro-inflammatory immune responses, one hypothesis may be that
the CS protein can downregulate excessive (TLR-driven) NF-kB
transcriptome responses, and result in a dramatically diminished
acute inflammatory response, thereby blunting subsequent CS
protein antigen specific adaptive immune responses [43]. This
may make biological sense, as infection of hepatocytes by malaria
sporozoites has been shown to induce the activation of NF-kBi na
MyD88 specific manner [44]. Expression of CS protein by the
parasite may have evolved to counteract this inflammatory
response and prevent excessive induction of malaria specific
adaptive immune responses in the infected host. Interestingly,
recent studies on an immunosuppressive drug (dehydroxymethy-
lepoxyquinomicin) that specifically interferes with the NF-kB-
importan a interaction was shown at lower doses to only modestly
affect IL-6 and TNFa levels, while dramatically affecting Th1
expansion, results paralleling those noted in our experiments [45].
These notions may also explain our findings, as well results
previously reported by others [15,34]. Those studies and ours
verify that at very high doses, rAd vaccines expressing CS protein
also show a trend toward diminished induction of CS protein
specific CMI responses (Figure 1) [15,34]. Multiple studies have
Figure 5. Co-expression of CS protein and EAT-2 increases the breadth of response against CS protein. Increased breadth of response
against CS protein epitopes was observed in mice co-vaccinated with Ad-CSP and Ad-EAT2 as compared to the control vaccine. Splenocytes from
groups of five BALB/cJ mice were collected and pooled together from 14 days post injection with either innate modulating treatments or control.
ELISpots were performed to measure IFNc secreting cells when stimulated with a CS protein peptide library made up of 52 15mers that overlap by 5
a.a. on either side. Wells that contained more than 15 spots were counted and compared between treatment groups (inset). (A) Mice were co-injected
IM with 5610
7 vps/mouse of Ad-CSP and 5610
7 vps/mouse of Ad-GFP/rEA or 5610
7 vps/mouse of Ad-CSP and 5610
7 vps/mouse of Ad-GFP. (B) Mice
were co-injected IM with 5610
7 vps/mouse of Ad-CSP and 5610
7 vps/mouse of Ad-EAT2 or 5610
7 vps/mouse of Ad-CSP and 5610
7 vps/mouse of
Ad-GFP. As a negative conrol, naı ¨ve splenocytes were also tested against paired peptides from the peptide pool, with an average background of
spots per paired peptides being only 2.2 spots.
doi:10.1371/journal.pone.0024147.g005
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possibly, the CS protein immunosuppressive effects are not
uncovered until an ‘‘NF-kB activation threshold’’ has been
broached, in this instance by use of excessively high doses of
rAd vaccines expressing CS protein, or by using more modest
doses of the Ad vaccine coupled with potent TLR activation.
Further studies will need to be performed to elucidate whether this
or other mechanisms may be responsible for our results.
Regardless, our data demonstrate the need to consider the impact
the inclusion of CS protein derived peptides, or the entire protein
along with other immunostimulatory compounds may have upon
present and future malaria specific vaccines. Taken together with
recent data demonstrating that protection from malaria challenge
can be independent of CS protein suggests that the use of CS
protein in certain malaria vaccine formulations will have to be
carefully considered [48,49].
In contrast to co-expression of the TLR agonist, co-expression
of EAT-2 and CS protein eventuated in the enhanced induction of
CMI responses to the CS protein, relative to the use of the Ad-
CSP vaccine alone. We have also previously observed a potent
CMI response against HIV derived Gag in mice treated with Ad-
EAT2+Ad-Gag [27]. Like TLRs, activation of the SLAM receptor
pathway in DCs and macrophages can also enhance the
production of pro-inflammatory cytokines [50].
The biochemical mechanism and intracellular signaling path-
way behind EAT-2’s ability to function as a T cell (and possibly a
B cell) stimulator in the face of CS protein over expression is not
fully elucidated, but is a question that has been unveiled by our
studies. SLAM associated proteins like EAT-2 are known to play a
role in several novel immunomodulatory pathways, including the
SLAM, CD22, and FccRIIB [51,52,53]. These pathways may not
be subject to the immune suppressive actions of CS protein
possibly by virtue of its specific mode of action relative to NF-kB
and/or TLR activation pathways described earlier.
It has been established that greater numbers of CD8
+ T cells are
required to police infected hepatocytes and achieve long term
protective immunity against malaria, emphasizing the importance
of inducing a large population of CD8
+ T cells capable of killing
Figure 6. Co-expression of CS protein and EAT-2 increases cytolytic activity of CS protein specific T cells. Co-vaccination of mice with
Ad-CSP and Ad-EAT2 increased specific killing cells pulsed with CS protein peptides. BALB/cJ mice (n=4) were co-injected IM with either 1610
8 vps/
mouse Ad-CSP and 1610
8 vps/mouse Ad-GFP or 1610
8 vps/mouse Ad-CSP and 1610
8 vps/mouse Ad-EAT2 on Day 0. Day 14 splenocytes were
collected from naı ¨ve mice and pulsed with either NYDNAGTNL peptide or an irrelevant peptide. NYDNAGTNL pulsed splenocytes were stained with a
high concentration of CFSE while splenocytes pulsed with irrelevant peptide were stained with a low concentration of CFSE. Stained splenocytes
were then combined in equivalent doses. 8 million cells were then injected IV into naı ¨ve, Ad-CSP+Ad-GFP co-vaccinated, or Ad-CSP+Ad-EAT2 co-
vaccinated mice. After 18 hrs splenocytes from these mice were collected and analyzed by flow cytometry to assess the amount of NYDNAGTNL
specific killing. % Specific killing = 1-((%CFSE
High/%CFSE
Low)immunized/(%CFSE
High/CFSE
Low)non-immunized). * denotes significant difference between
treatments p,0.05.
doi:10.1371/journal.pone.0024147.g006
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related to increased breadth of the CMI response in addition to
the potency of the CMI response [35,36,37]. Here, as an accessory
to the increased CMI response, we have demonstrated Ad-EAT2s
ability to stimulate increased T cell responses against multiple CS
protein epitopes. We not only observed an increase in the
percentage of CS protein specific CD8
+ T cells, but also improved
in vivo CTL killing of CS pulsed splenocytes from mice treated with
Ad-CSP+Ad-EAT2. The use of EAT-2 to augment CSP specific
functional CD8
+ T cells may be of greatest importance in killing
Plasmodium infected hepatocytes, as these types of responses are not
only positively correlated with protective capability, but also may
outweigh the need for induction of malaria antigen specific
antibody responses [4,5,54,55].
Improvements over sole use of Ad-CSP to induce CS protein
antigen specific B cell responses were not achieved in mice treated
with either Ad-CSP vaccine cocktail. However, co-vaccination
with the Ad-CSP and Ad-EAT2 vectors at least prevented the loss
of induction of CS specific antibody responses noted after use of
the Ad-GFP/rEA and Ad-CSP vaccine combination. These results
did not appear to be due to a skewing from Th2t oT h1 type
antibody response, as measured by IgG1/IgG2a ratios, there were
also no observed differences in IFNc secreting CD8
- CD3
+ T cells
between treatment groups. Further research will need to be
performed to elucidate the reasons behind the observed antibody
responses.
The importance of stimulating a strong cytotoxic T cell response
against P.falciparum infected hepatocytes is vital in creating a
subunit based vaccine that is protective against malaria. With this
study we have successfully stimulated a CMI response to CS
protein that can overcome CS protein related adaptive immune
response ablation and is even more potent than the previous
generation of rAd5s expressing CS protein. Incorporation of this
new vaccine platform into ongoing or future malaria vaccine trials
could potentially achieve the levels of prophylaxis needed to
protect vulnerable populations against natural malaria infections.
Future studies will need to be performed to assess this platforms
ability to protect larger animals challenged with malaria.
Supporting Information
Figure S1 CS protein sequence. The CS protein sequence
utilized for constructing the Ad-CSP vaccine was designed based
on several known CS protein sequences. The NYDNAGTNL
peptide’s location is underlined in the sequence. Bold font within
the sequence indicates the repeat region of CS protein. The
location of the Thrombospondin-like Type 1 repeat region (TSR
domain) is indicated by gray font.
(TIF)
Figure S2 Ad-CSP construction. Recombinant Ad-CSP was
constructed by creating a codon optimized CS protein sequence
flanked by NheI sites in a pGA4 plasmid. The sequence was
excised with the Nhe1 and cloned into a pShuttle containing a
CMV expression cassette. The resulting plasmid was linearized
with PmeI and recombined with pAdeasyI Ad5 vector in BJ 5183
cells. pAd-CSP was then purified and linearized with PacI enzyme
and transfected into HEK 293 cells from which Ad-CSP was
purified using cesium gradients.
(TIF)
Figure S3 CS protein expression does not interfere with
antigen specific immune responses against other trans-
genes at low doses. Co-vaccination with Ad-gag+Ad-CSP did
not result in decreased gag specific immune responses. BALB/cJ
mice were injected with 5610
5 vp/mouse of Ad-gag and 5610
7
vp/mouse of Ad-CSP or 5610
5 vp/mouse of Ad-gag and 5610
7
vp/mouse of Ad-GFP. Splenocytes were collected 14 dpi and
assayed by ELISpot for CS protein peptide (NYDNAGTNL)
specific IFNc secretion (A) or gag peptide (AMQMLKETI)
specific IFNc secretion (B). The bars represent mean 6 SD.
Statistical analysis for Supplemental Figure 3A included other
peptides tested from the peptide library that are not displayed in
the graph. Two Way ANOVA with Student-Newman-Keuls post-
hoc test (A) or One Way ANOVA with a Student-Newman-Keuls
post-hoc test (B) were utilized for statistical analysis. **,*** denotes
significance between treatments, p,0.01, p,0.001.
(TIF)
Figure S4 Ad-GFP/rEA combined with 5610
7 vp/mouse
of Ad-CSP begins to display a diminished CS protein
specific CMI response after a dose of 5610
6 vp/mouse.
Figure 7. Induction of CS protein specific antibody responses
by Ad-CSP vaccines augmented by rEA or EAT-2. Total IgG
antibody against CS protein is ablated in Ad-CSP+Ad-GFP/rEA co-
vaccinated mice while Ad-CSP+Ad-EAT2 co-vaccinated mice demon-
strated significantly more CS protein specific IgG than naı ¨ve animals.
BALB/cJ mice (n=5) were co-injected IM with 5610
7 vps/mouse of Ad-
CSP and 5610
7 vps/mouse of Ad-GFP or 5610
7 vps/mouse of Ad-CSP
and 5610
7 vps/mouse of either (A) Ad-GFP/rEA or (B) Ad-EAT2. Plasma
was collected at day 14. Total IgG against CS protein in the plasma was
measured by ELISA. The bars represent mean 6 SD. Statistical analysis
was completed using One Way ANOVA with a Student-Newman-Keuls
post-hoc test, * Denotes significance over naı ¨ve p,0.05. { Denotes
significant difference between treatments p,0.05.
doi:10.1371/journal.pone.0024147.g007
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6 vp/mouse do
we observe a diminished CS specific CMI response when
combined with 5610 vp/mouse of Ad-CSP. BALB/cJ mice were
injected with doses ranging from 5610
6 to 5610
8 vp/mouse of
Ad-GFP/rEA combined with 5610
7 vp/mouse of Ad-CSP.
Splenocytes were collected 14 dpi and were analyzed by flow
cytometry for NYDNAGTNL tetramer
+ CD3
+ and CD8
+ cells (A)
or ELISpot for CS protein specific IFNc secretion (B). Statistical
analysis was completed using One Way ANOVA with a Student-
Newman-Keuls post-hoc test, *** denotes significance between
treatments, p,0.01, p,0.001.
(TIF)
Figure S5 Expression of GFP does not interfere with CS
protein specific CMI responses. Co-injection of Ad-GFP
does not interfere with Ad-CSP initiated CS protein specific CMI
responses. BALB/cJ mice were co-injected with 5610
7 vp/mouse
of Ad-GFP and 5610
7 vp/mouse of Ad-CSP or 5610
7 vp/mouse
of Ad-Null and 5610
7 vp/mouse of Ad-CSP. Splenocytes were
collected 14 dpi and cells were measured for NYDNAGTNL tet
+,
CD3
+, CD8
+ T-cells. Both treatments had a higher percentage of
CS protein specific tet
+, CD3
+, CD8
+ T-cells than Naı ¨ve with no
difference observed between Ad-CSP+Ad-Null and Ad-CSP+Ad-
GFP. Statistical analysis was completed using One Way ANOVA
with a Student-Newman-Keuls post-hoc test, *** denotes signif-
icance between treatments, p,0.01, p,0.001.
(TIF)
Figure S6 Improved degranulation of CD8+ T cells in
mice co-vaccinated with Ad-CSP and Ad-EAT2. Degranu-
lation marker, CD107a, expression in CD8
+ T cell from mice co-
vaccinated with Ad-CSP+Ad-EAT2 or Ad-CSP+Ad-GFP. Sple-
nocytes were collected from BALB/cJ mice 14 days post co-
injection of either 5610
7 vps of Ad-CSP and 5610
7 vps of Ad-
GFP or 5610
7 vps of Ad-CSP and 5610
7 vps of Ad-EAT2. 2610
6
splenocytes from naive or mice co-vaccinated with either
treatment were stimulated with 2ug NYD-peptide at 37uC for 3
days. Cells were then washed with FACS buffer and stained with
CD8-Alexa700, CD107-FITC antibodies and viability dye
(ViViD) and ran on LSR-II. % of live CD107+ CD3+ T cells is
shown. The bars represent mean 6 SD. Statistical analysis was
completed using One Way ANOVA with a Student-Newman-
Keuls post-hoc test,* Indicates significance over naı ¨ve p,0.05.
(TIF)
Figure S7 Sub-isotype analysis of IgG antibody from
plasma of mice co-vaccinated with Ad-CSP and Ad-
EAT2. BALB/cJ mice (n=6) were co-injected i.m. with 5610
7
vps of Ad-CSP and 5610
7 vps of Ad-GFP or 5610
7 vps of Ad-
CSP and 5610
7 vps of Ad-EAT2. Plasma was collected at day 14.
(A) The amount of CS protein specific IgG subisotypes was
measured by ELISA. (B) The ratio of IgG2a/IgG1 was calculated
to indicate the Th1t oT h2 response ratio. The bars represent
mean 6 SD. Statistical analysis for sub-isotyping (A) was
completed using One Way ANOVA with a Student-Newman-
Keuls post-hoc test and standard t-test was performed for Th1t o
Th2 ratios (B),* indicates significance over naı ¨ve p,0.05. {
Indicates significance between treatments p,0.05.
(TIF)
Figure S8 CD3
+ CD8
2 IFNc
+ cells respond similarly to
both vaccine regimens. Co-vaccination with Ad-CSP and Ad-
EAT2 resulted in similar IFNc secretion from CD3
+ CD8
2 T
cells. BALB/cJ mice (n=6) were co-injected IM with 5610
7 vps/
mouse of Ad-CSP and 5610
7 vps/mouse of Ad-EAT2 or 5610
7
vps/mouse of Ad-CSP and 5610
7 vps/mouse of Ad-GFP.
Splenocytes were stimulation with NYDNAGTNL peptide. Cells
were stained with CD8-Alexa Flour700, CD3-APC-Cy7, ViViD,
and IFNg-APC. The bars represent mean 6 SD. Statistical
analysis was completed using One Way ANOVA with a Student-
Newman-Keuls post-hoc test.
(TIF)
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